ClinicalTrials.gg
RecruitingNCT07097701Updated Dec 22, 2025

An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR Compared to Mexiletine IR

A Phase 3 interventional study of Granular powder in unit dose foil-lined sachet Mexiletine (PR) and Oral Capsule Mexiletine (IR) in Myotonia, sponsored by Lupin Ltd.. Recruiting at 1 site in Belgium. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Lupin Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

An Open-Label, Randomized, Cross-Over Study to Investigate the Efficacy and Safety of Mexiletine PR compared to Mexiletine IR in Patients with Non-Dystrophic Myotonias (ACHILLES study)

Read the detailed description

This is a multicenter, open-label, randomized, cross-over study intended to evaluate the efficacy and the safety of mexiletine PR (QD) vs mexiletine IR (TID) in patients with non-dystrophic myotonias including myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM). The study will consist of a 4-week screening period followed by two 12-week treatment periods. Eligible patients will be randomized to receive mexiletine PR or mexiletine IR for 12 weeks. After a wash out period of at least 7 days the patients will receive the opposite treatment for 12 weeks.

A total of 24 patients are planned to be enrolled (with a target enrollment of 12 naïve to previous mexiletine treatment and 12 previously treated with mexiletine).

Safety assessments include patient- and physician-reported adverse event reporting, electrocardiogram (ECG), standard clinical laboratory evaluations, physical examinations, and vital signs. Efficacy assessments include patient-reported outcomes (PROs) and functional capacity outcome measures.

02

Conditions studied

  • Myotonia

Browse trials for

03

In context

Myotonia

17 studies on the registry are indexed under Myotonia; 7 are open to participants now.

This study's planned enrollment of 24 is below the median of 44 across 13 interventional studies indexed under Myotonia.

Browse Myotonia studies →

Lead sponsor

Lupin Ltd. is the lead sponsor of 16 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to comprehend and willingness to sign an (ICF) or ICF of the parent(s)/legal guardian and written assent from the patient (if patient \< 18 years of age);
  2. Non-dystrophic myotonias including myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM) confirmed genetically;
  3. Male or non-pregnant female ≥16 years and older at screening;
  4. (BMI) of 18.5 kg/m2 to 30 kg/m2, and weight ≥45 kg;
  5. Female patients of must be using a highly effective form of for the duration of the study and for at least 30 days after last dose of study drug. Male patients must use birth control for the duration of the study and for at least 30 days after last dose of study drug;
  6. No significant cardiac abnormalities as determined by a cardiologist including (ECG) and echocardiogram not older than 3 months prior to study entry;
  7. Participants with myotonic symptoms severe enough to justify treatment (in the opinion of the study investigator);
  8. Presence of clinical handgrip myotonia (delayed relaxation of grip of ≥ 3 second using a stopwatch) at screening (naïve patients only) and on Day 1 (pre-dose) (patients naïve and previously treated with mexiletine).

Exclusion criteria

Exclusion Criteria

  1. Are pregnant or lactating;
  2. Have any one of the following medical conditions: uncontrolled diabetes mellitus, cancer other than skin cancer less than five years previously (e.g., basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC) of skin allowed), multiple sclerosis, seizure disorders, or other serious medical illness or has any other condition, which in the opinion of the Investigator, precludes the participant's participation in the study or the participant is unlikely to comply with the protocol-defined procedures and therefore is unlikely to complete the study;
  3. Severe renal impairment ( (GFR) \< 30 mL/min);
  4. Medical conditions which could interfere with muscle function such as infections, trauma, fractures, or planned surgery;
  5. Medical conditions that could affect hand functioning including but not limited to rheumatoid arthritis, Dupuytren's contracture, hand deformity, etc.;
  6. Severe arthritis or medical condition (other than NDM) that would significantly impact ambulation;
  7. Severe hepatic impairment or preexisting elevated liver function tests > 3 times the (ULN) at screening ( (ALT)/aspartate transaminase (AST), gamma-glutamyl transferase (GGT)) and/or any abnormal chemistry, hematology or urine lab considered by the investigator;
  8. Serum potassium values \< 3.5 mmol/L or > 5.0 mmol/L or serum magnesium values \< 1.7 mg/dL. Electrolytic imbalance such as hypocalcaemia, hypercalcaemia, hypokalaemia, hyperkalaemia or hypomagnesaemia may increase the proarrhythmic effects of mexiletine. Electrolyte imbalances need to be corrected before administering mexiletine and will be monitored throughout treatment.
  9. Intake of any other anti-myotonic treatment within 4 weeks prior to baseline (Day 1) or 5 half-lives, whichever is longer (e.g., metformin, propafenone, flecainide, lamotrigine, carbamazepine or any other channel-blocker/anticonvulsive drugs;
  10. Use of any concomitant medications that could increase the cardiac risk or increases the risk of adverse reactions (see Section 6.8 for a complete list of prohibited concomitant medications);
  11. Known allergy to mexiletine or any of the or any local anesthetics;
  12. Participation in another interventional clinical study during the last 3 months or 5 half-lives of the medicinal product, whichever is longer;
  13. Wheelchair-bound or bedridden;
  14. Any cardiac safety-associated condition including any of the following criteria detected by screening cardiac evaluations including , echocardiogram and clinical evaluations (see protocol Section 5.3 for a detailed list);
  15. Current smokers (within one month of the screening visit) (eg, cigarettes, cigars, vape/e-cigarette products, etc.);
  16. Subgroup 'mexiletine-naïve': patients with previous treatment with mexiletine are excluded. Subgroup 'previous mexiletine treatment': patients with treatment with mexiletine within 1 week prior to baseline (Day 1) are excluded
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
24 participants (estimated)

Study arms

  • Active comparator
    Mexiletine prolonged-release (PR)

    Mexiletine PR 167 mg (mexiletine HCl 200 mg) Mexiletine PR 333 mg (mexiletine HCl 400 mg) OR Mexiletine PR 500 mg (mexiletine HCl 600 mg)

    Drug: Granular powder in unit dose foil-lined sachet Mexiletine (PR)

  • Active comparator
    Mexiletine immediate release (IR)

    Mexiletine IR 167 mg (mexiletine HCl 200 mg)

    Drug: Oral Capsule Mexiletine (IR)

Interventions

  • DrugGranular powder in unit dose foil-lined sachet Mexiletine (PR)

    Mexiletine (PR)

  • DrugOral Capsule Mexiletine (IR)

    Mexiletine (IR)

06

What researchers measure

Primary outcomes

  1. To compare the safety of mexiletine PR vs mexiletine IR by incidence of treatment emergent Adverse Events (TEAEs), treatment-related TEAEs, serious AEs, and patient discontinuation rate between mexiletine PR and mexiletine IR after 12 weeks of treatment.

    To compare the safety of mexiletine PR vs mexiletine IR for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonias (myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM)) by incidence of treatment emergent Adverse Events (TEAEs), treatment-related TEAEs, serious AEs, and patient discontinuation rate between mexiletine PR and mexiletine IR after 12 weeks of treatment.

    Time frame: Baseline to week 24

  2. To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in QTc intervals by12-lead in ECG

    To compare the safety of mexiletine PR vs mexiletine IR for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonias (myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM)) by mean change from baseline in QTc Intervals by12-lead in ECG

    Time frame: Baseline to week 24

  3. To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in PR intervals by12-lead in ECG

    To compare the safety of mexiletine PR vs mexiletine IR for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonias (myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM)) by mean change from baseline in PR intervals by12-lead in ECG.

    Time frame: Baseline to week 24

  4. To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline in QRS intervals by12-lead in ECG

    To compare the safety of mexiletine PR vs mexiletine IR for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonias (myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM)) by mean change from baseline in QRS intervals by12-lead in ECG

    Time frame: Baseline to week 24

  5. To compare the safety of mexiletine PR vs mexiletine IR by mean change from baseline by average minimum heart rate by12-lead in ECG

    To compare the safety of mexiletine PR vs mexiletine IR for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonias (myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM)) by mean change from baseline in average heart rate by 12-lead in ECG

    Time frame: Baseline to week 24

  6. To compare the safety of mexiletine PR vs mexiletine IR by performing physical examiniations

    To compare the safety of mexiletine PR vs mexiletine IR for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonias (myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM)) by performing physical examinations. The investigator will complete a physical examination including the following regions and systems: general appearance, head and neck, heart, lung, abdomen, chest and back, upper extremities, lower extremities, neurological, and dermatological. In addition, height and weight will be recorded.

    Time frame: Baseline to week 24

  7. To compare the safety of mexiletine PR vs mexiletine IR by assessing vital signs

    To compare the safety of mexiletine PR vs mexiletine IR for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonias (myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM)) by assessing vital signs. Vital signs will be obtained at each study visit and will include pulse, respiration, body temperature, and blood pressure. Unscheduled vital sign measurements may be obtained at the investigator's discretion during the study.

    Time frame: Baseline to week 24

  8. To compare the safety of mexiletine PR vs mexiletine IR by performing standard clinical laboratory evaluations

    To compare the safety of mexiletine PR vs mexiletine IR for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonias (myotonia congenita (MC), paramyotonia congenita (PC) and sodium channel myotonia (SCM)) by performing standard clinical laboratory evaluations. Clinical laboratory samples will be collected under fasting conditions and hematology, serum chemistry, and urinalysis assessments will be performed

    Time frame: Baseline to week 24

Secondary outcomes

  1. Mean change in handgrip relaxation time

    Opening Time (VHOT) functional evaluation by mean change in maximal voluntary isometric contraction (MVIC) and relaxation time by Video-recording of Hand. The dominant wrist and hand are placed on a bedside table with the forearm fully supinated. The patient is asked to open the hand after making a tight fist for 3-5 seconds 2 times within 30 minutes.

    Time frame: Baseline to week 24

  2. Mean change in health-related quality of life

    Mean change in health-related quality of life (measured by INQoL) on a 7-point Likert scale

    Time frame: Baseline to week 24

  3. Mean change in MBS scores

    Mean change in Myotonia Behavior Scale (MBS) scores on a 0-5 rating scale

    Time frame: Baseline to week 24

  4. Mean change in time to perform Timed-up and go (TUG) test

    Mean change in time (seconds) to perform Timed-up and go (TUG) test

    Time frame: Baseline to week 24

  5. Mean change in VAS

    Score for muscle stiffness (myotonia severity) as self-reported by patients on a Visual Analog Scale (VAS) on a 1-100 rating scale.

    Time frame: Baseline to week 24

  6. Mean change in Clinical Global Impression (CGI) - Efficacy Scale

    Score for Clinical Global Impression (CGI) - Efficacy by a 5 rating scale of No Symptoms to Very Severe

    Time frame: Baseline to week 24

  7. Mean change in Clinical Global Impression (CGI) - Tolerability Index Scale

    Mean change in Clinical Global Impression (CGI) - Tolerability Index Scale by a 7 rating scale of much worse to much better

    Time frame: Baseline to week 24

  8. Mean change in time to perform the 10-meter Walk Test

    Mean change in time (seconds) to perform the 10-meter Walk Test (10mWT) 10mWT is a performance-based test assessing walking in two different conditions, own preferred speed and maximum speed, over a short distance. The time taken to walk 10 meters at usual comfortable and maximum speed is recorded with a stopwatch.

    Time frame: Baseline to week 24

  9. Mean change in Gastrointestinal function: The Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQoL)

    Mean change in Gastrointestinal function: The Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQoL) by a 5 scale of no symptoms to Symptoms are incapacitating, unable to do daily activities

    Time frame: Baseline to week 24

  10. Mean change in CMRS Scale

    Mean change in Clinical myotonia rating scale (CMRS)

    Time frame: Baseline to week 24

  11. Mean change Swallowing function

    Mean change in Swallowing function: timed testing of swallowing

    Time frame: Baseline to week 24

  12. Preference between the two study treatments

    Patients were also asked to give their preference between the 2 periods of treatment and to provide the primary reasons for their choice.

    Time frame: Baseline to week 24

07

Study locations

1 of 1 sites recruiting
  • Universitair Ziekenhuis Leuven"UZ Leuven Gasthuisberg Campus Herestraat 49 Leuven, 3000"
    Leuven, Belgium
    Recruiting
    • Kristi Claeys · Contact
    • Kristi Claeys · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jan 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2024
First posted
Jul 31, 2025
StartActual
Sep 3, 2025
Primary completionEst.
Jan 22, 2027
CompletionEst.
Feb 22, 2027
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07097701
Lead sponsor
Lupin Ltd.
Collaborators
Lupin Atlantis Holdings S.A.
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Sep 3, 2025
Primary completion
Jan 22, 2027 (estimated)
Completion
Feb 22, 2027 (estimated)
Last update
Dec 22, 2025

Study contacts

Nikki Adetoro
Contact
nikkiadetoro@lupin.com
4434474534

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion